Veryan Medical will support Vasorum in US commercialisation of Celt arterial closure device

Vasorum Celt ACD
Celt ACD

Vasorum and Veryan Medical have announced that from today Veryan Medical will support Vasorum in the commercialisation of the Celt arterial closure device (ACD) in the USA.

According to a press release, the Celt ACD has been used in more than 60,000 patients to date with excellent clinical results following percutaneous catheter-based vascular procedures.

Vasorum co-founder and CEO, James Coleman said, “The Veryan Medical agreement is validation that the Celt ACD has proven itself to be a leading arterial closure device that allows rapid and complete haemostasis independent of vascular anatomy, including calcified arteries. This agreement provides an opportunity to accelerate growth for both companies in the USA.”

“We are pleased to be working with Vasorum and the Celt ACD which has proven to be a game changing closure technology” said Nick Yeo, Veryan Medical’s CEO. “We plan to include the Celt device as an option in our MIMICS-3D USA registry which will start enrolling later this year. MIMICS-3D USA is a prospective, multicentre observational study evaluating the safety, effectiveness and device performance of the BioMimics 3D vascular stent system within a real-world clinical population of patients undergoing femoropopliteal intervention.”

He continued: “MIMICS-3D-USA will enrol more than 500 patients in 40 clinical sites across the USA and Veryan will conduct a sub-analysis of patients who have had a Celt ACD used in the index procedure. Veryan is proud to support innovators like Vasorum to provide insights, marketing strategy, and a top-tier salesforce to ensure commercial success and clinical adoption. The Celt ACD and Veryan’s novel BioMimics 3D stent together represent an exciting combination both for our sales team and our customers.”

Syed Hussain, chairman of Vascular & Endovascular Surgery at the Christie Clinic in Champaign, USA commented, “I have been using the Celt ACD for several years and have completed over 1,000 implants. The device is extremely easy to use and has unique benefits including rapid haemostasis allowing for safe patient ambulation shortly after the procedure.”


Please enter your comment!
Please enter your name here